Remove 2027 Remove Disease Remove Trials
article thumbnail

PFIZER CONFIRMS U.S. PATENT TERM EXTENSION FOR IBRANCE UNTIL MARCH 2027

The Pharma Data

RE47,739 (‘739) by more than four years until March 5, 2027. Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with CDK4/6 inhibitors, including IBRANCE when taken in combination with endocrine therapy. Across clinical trials (PALOMA-1, PALOMA-2, PALOMA-3), 1.0%

article thumbnail

The Biotech Startup Contraction Continues… And That’s A Good Thing

LifeSciVC

Further, this lemming challenge has also moved well beyond oncology – think of all the “not-so-fast follower” autoimmune programs or metabolic disease stories. Further, the competitive intensity in certain areas makes the “clinical do-ability” too challenging, even if those drugs could likely be beneficial.

DNA 110
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Article EMA Thank You What we expect European regulators to do in August and September 2024

Agency IQ

For example, on July 25, the Hungarian presidency hosted an informal meeting of health ministers to discuss health issues, such as mitigating the effect of cardiovascular diseases and implementing the European Health Data Space (EHDS).

article thumbnail

AI-Designed Drugs vs. Traditional Drug Discovery: Pros and Cons

Vial

billion by 2027 , at a compound annual growth rate (CAGR) of 45.7% As a result of this shorter timeline, AI-designed drugs also offer the potential to reduce the cost of drug discovery because the traditional process of drug discovery typically involves expensive and time-consuming clinical trials to evaluate promising compounds.

Drugs 52
article thumbnail

Amgen Named To Dow Jones Sustainability World Index For Eighth Consecutive Year

The Pharma Data

.” Amgen’s four ESG pillars – Healthy People, Healthy Society, Healthy Environment and a Healthy Amgen – include commitments to: Achieve carbon neutrality by 2027, along with a 40% reduction in water used and a 75% reduction in waste disposed.

article thumbnail

AMGEN RECOGNIZED FOR OUTSTANDING ESG PERFORMANCE

The Pharma Data

.” Amgen’s four ESG pillars – Healthy People, Healthy Society, Healthy Planet, and a Healthy Amgen – include commitments to: Achieve carbon neutrality by 2027, along with a 40% reduction in water used and a 75% reduction in waste disposed.

article thumbnail

BridgeBio Pharma, Inc. Prices Upsized Offering of $650 Million Convertible Senior Notes

The Pharma Data

This activity could increase (or reduce the size of any decrease in) the market price of the Company’s common stock, the notes or the Company’s 2.50% Convertible Senior Notes due 2027 at that time. BridgeBio’s pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.